Table 4 Clinical outcomes and the association between nafamostat dose and outcomes. The association with each outcome was assessed using distinct generalised linear models, each adjusted for confounding factors appropriate to the respective outcome, as detailed in eTable 2
Outcome | Overall (n = 269) | Adjusted OR | β | 95%CI | p value |
|---|---|---|---|---|---|
ICU mortality | 61 (22.7%) | 0.95 | (0.90, 0.99) | 0.04 | |
Hospital mortality | 94 (34.9%) | 0.95 | (0.91, 0.99) | 0.03 | |
ICU length of stay, day | 14 ± 21.1 | 0.04 | (-0.35, 0.44) | 0.83 | |
Hospital length of stay, day | 66 ± 91.6 | 0.17 | (-1.55, 1.89) | 0.85 | |
Mechanical ventilation days, day | 8 ± 17.9 | 0.13 | (-0.11, 0.37) | 0.30 | |
ΔC-reactive protein, mg/dL | 1.49 ± 9.21 | -0.03 | (-0.15, 0.09) | 0.67 | |
Red blood cell over 48 h, ml | 200.5 ± 377.8 | -13.7 | (-19.9, -7.5) | < 0.001 | |
Fresh frozen plasma over 48 h, ml | 241.1 ± 667.1 | -22.9 | (-34.1, -11.7) | < 0.001 | |
Platelet over 48 h, ml | 64.0 ± 162.5 | -4.1 | (-6.9, -1.2) | 0.01 | |
Dialysis dependence at discharge* | 68 / 182 (37.4%) | 0.95 | (0.90, 1.00) | 0.05 |